Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 + PEG-Interferon in HCV Cirrhosis Non-Responders
NCT00039962Phase 3Completed
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- May 2002
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C (HCV) comparing Thymalfasin + PEG-IFN with Placebo + PEG-IFN (2 arms). Primary endpoints: Sustained Virologic Response at 72 weeks and Histologic Improvement at 72 weeks. Started May 2002; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00039962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039962.